OPL-CCL2-LPM ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
66. IgA nephropathy
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00856674 (ClinicalTrials.gov) | March 2009 | 4/3/2009 | Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy | A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy | IGA Nephropathy;Proteinuria | Biological: OPL-CCL2-LPM | Osprey Pharmaceuticals USA, Inc. | NULL | Terminated | 18 Years | N/A | Both | 30 | Phase 1 | Canada |